• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

What We're Reading: Few Hospitals Receive 5 Stars in Medicare's New Ratings


What we're reading, July 28, 2016: CMS released first hospital quality ratings; Anthem is prepared to fight the government over Cigna purchase; and regulations are falling behind stem cell clinics.

Of the 3617 hospitals rated in CMS’ first hospital quality rating, just 102 received the top rating of 5 stars. According to Kaiser Health News, many of the nation’s best-known hospitals received average or below-average scores as part of the controversial rating system. Hospitals argue the ratings do not do enough to factor in the health of the patients being treated, which makes the hospitals that treat tougher cases look bad.

Anthem is prepared to fight the US Department of Justice (DOJ)’s efforts to block its acquisition of Cigna. Expecting to lose money on plans sold under the Affordable Care Act, Anthem is arguing that a merger with Cigna would let it negotiate better prices and pass savings on to consumers, reported Reuters. Last week, the DOJ sued to block Anthem’s acquisition of Cigna and Aetna’s purchase of Humana.

Although stem cell therapies are mostly theory at this point, new stem cell clinics are spreading as regulations fall behind. The New York Times blog The Upshot took a look at the world of stem cell clinics and how they are operating by working around the current laws in place. FDA does allow clinics to inject patients with their own stem cells, as long as cells meet certain criteria, but some of the treatments being advertised seem to flout FDA regulations.

Related Videos
Dr Guru Sonpavde
Video 2 - "Adverse Events & Existing Treatment Options for Dry Eye Disease"
Overview of Dry Eye Disease (DED) Causes and Treatments
Video 12 - "Harnessing Indication-Specific Data on Biosimilars"
Video 11 - "An Overview of Biosimilar Extrapolation During FDA Approval"
Video 3 - "Overview of BCG-Unresponsive Bladder Cancer Treatments Landscape"
Video 2 - "Bladder Cancer with FGFR Alterations: THOR-2 Cohort 1 Study at ESMO 2023"
Related Content
© 2023 MJH Life Sciences
All rights reserved.